

# Custom Tailored Research on Novo Nordisk A/s

## Corporate Data

Source: Thomson Reuters

### Officers

Helge Lund, Director Lars Fruergaard Joergensen, Director Jeppe Christiansen, Director Karsten Munk Knudsen, Director Maziar Mike. Doustdar, Director

### Address

Novo Alle 1  
BAGSVAERD, undefined 2880  
Phone: (44) 448-888  
Fax: (44) 436-633

## Company Description

Source: Thomson Reuters

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

## Fundamentals

Source: Thomson Reuters

Previous Close Price (6/08/21)	<b>\$82.28</b>
Volume (6/08/21)	<b>151.0</b>
Average Daily Share Volume	<b>1.0 M</b>
Shares Outstanding	<b>1.8 B</b>
Market Cap	<b>\$145.6 B</b>
Trailing 12 Month EPS	<b>\$3.01</b>
P/E Ratio	<b>27.3</b>
Gross Margin	<b>83.17%</b>
Beta	<b>0.4</b>
Employees	<b>45,157</b>
Trailing 12 Month Revenue	<b>\$20.8 B</b>
Return on Equity	<b>75.94%</b>
Annual Dividend Rate	<b>1.44</b>

## Valuation Overview

Source: Thomson Reuters

Price/Earnings (P/E)	<b>27.3x</b>
P/E Industry Average	<b>31.4x</b>
Price/Sales	<b>7.0x</b>
Price/Sales Industry Average	<b>26.8x</b>
Price/Book	<b>4.6x</b>
Price/Book Industry Average	<b>9.2x</b>
Price/Cash Flow	<b>18.2x</b>
Price/Cash Flow Industry Average	<b>24.3x</b>
Gross Margin	<b>83.2%</b>
Gross Margin Industry Average	<b>66.3%</b>

## Valuation Ratios

Source: Thomson Reuters

Price/Earnings (P/E)	<b>27.3x</b>
P/E Industry Average	<b>31.4x</b>
Price/Sales	<b>7.0x</b>
Price/Sales Industry Average	<b>26.8x</b>
Price/Book	<b>4.6x</b>
Price/Book Industry Average	<b>9.2x</b>
Industry High <b>1</b> - <b>10</b> Low	Industry Average <b>1</b>

## Profitability

Source: Thomson Reuters

Gross Margin	<b>83.2%</b>
Gross Margin Industry Average	<b>66.3%</b>
Operating Margin	<b>41.6%</b>
Operating Margin Industry Avg	<b>-41.1%</b>
Profit Margin	<b>33.8%</b>
Profit Margin Industry Average	<b>-46.7%</b>
Industry High <b>1</b> - <b>10</b> Low	Industry Average <b>1</b>

## Effectiveness

Source: Thomson Reuters

Return On Equity (ROE)	<b>75.9%</b>
ROE Industry Average	<b>18.1%</b>
Return On Assets (ROA)	<b>32.0%</b>
ROA Industry Average	<b>6.2%</b>
Return On Investment (ROI)	<b>64.9%</b>
ROI Industry Average	<b>9.1%</b>
Industry High <b>1</b> - <b>10</b> Low	Industry Average <b>1</b>


## Growth Rates

Source: Thomson Reuters

PEG Ratio	<b>3.2</b>
PEG Ratio Industry Average	<b>3.8</b>
TTM Revenue	<b>0.2%</b>
TTM Revenue Industry Average	<b>21.6%</b>
MRQ Earnings Per Share	<b>7.9%</b>
MRQ EPS Industry Average	<b>21.3%</b>
Industry High <b>1</b> - <b>10</b> Low	Industry Average <b>1</b>


## Revenue Trend

Source: Thomson Reuters




## Cash From Operations

Source: Thomson Reuters



## Cash & Short Term Inv.

Source: Thomson Reuters



# Custom Tailored Research on Novo Nordisk A/s

## Performance within Industry

Source: Thomson Reuters

Company Statistics

Market Cap



Total Revenue TTM



Profit Margin



Performance

52-Week Change



Beta



Dividend Yield



Growth Rate

Earnings Growth 5yr



Sales Growth 5yr



PEG Ratio



Industry High 1 - 5 Low

The orange box in each of these graphs indicates the position NVO holds in relation to the rest of its industry, with 1 being the group that is performing the best within the industry.


## Insider Trading

Source: Thomson Reuters

No Insider Trading Activity

## Earnings Analysis

Source: Thomson Reuters



NVO reported 1st quarter 2021 earnings of \$0.89, beating the consensus estimate of the 2 analysts covering the company by 6.72%. This positive surprise is particularly noteworthy because the guidance for the quarter had risen 9.21% in the year leading up to the

## Price Target History

Source: Thomson Reuters




## 1 Year Price History

Source: Thomson Reuters



## 3 Month Price History

Source: Thomson Reuters



# Custom Tailored Research on **Novo Nordisk A/s**

---



©2021 Thomson Reuters. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. Thomson Reuters and the Kinesis logo are trademarks of Thomson Reuters and its affiliated companies. [www.thomsonreuters.com](http://www.thomsonreuters.com)

TD Ameritrade, Inc., member FINRA/SIPC. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank. ©2021 TD Ameritrade.

---